~~<i id='864A91ACB2'><strike id='864A91ACB2'><tt id='864A91ACB2'><pre id='864A91ACB2'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

entertainment

author：Wikipedia 2025-09-29 21:26:53 - browse：145

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

Editas Medicine, the winner of that battle in the U.S., will now cash in.

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Steward Health Care Massachusetts hospitals face fiscal disaster

entertainment

knowledge

explore

focus

explore

hotspot

AdobeAsaboygrowingupwithhemophiliaA,NoahFrederickreservedtheendofhisannualcheckupstotalkaboutnewtech

WSS

Dementia risk linked to living in disadvantaged areas: Study

5 dead in mass shooting on Caribbean island of St. Vincent: Police

The stock market has soared this year, but will it last? Experts weigh in

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Hormonal contraceptives don’t actually treat endometriosis

Readout Newsletter: Bristol, Sangamo, Gilead, and more

leisure time

entertainment

entertainment

Peter Hotez and the public health issue of online harassment

After a decade, new Gardasil ad campaign gets it (mostly) right

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

A new ‘biological computer' targets cancer while sparing healthy cells

FDA approval of Sarepta Duchenne genetic therapy gives me hope

After a decade, new Gardasil ad campaign gets it (mostly) right

In age of alternative facts, a scholarly course on calling out crap

Why scientists need input from humanists on sensitive research

Hepatitis C has a cure — but many Americans still lack access to it

Are infertility treatments 'essential' during the Covid

knowledge

Caribou posts encouraging results on off

A new ‘biological computer' targets cancer while sparing healthy cells

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

'CMA Fest' 2023: How to watch, who is performing and more

Judge denies Trump's request for new trial in E. Jean Carroll case

'CMA Fest' 2023: How to watch, who is performing and more

explore

focus

explore

hotspot